ClinicalTrials.gg
Status unknownNCT03692858Updated Oct 22, 2019

IPACK Block in Total Knee Arthroplasty

A Phase 2 interventional study of Adductor Canal Block plus IPACK Block and Adductor Canal Block in Total Knee Arthroplasty, sponsored by Asklepieion Voulas General Hospital. Status unknown at 1 site in Greece. Open to participants aged 14 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-10-22.

Sponsored by Asklepieion Voulas General Hospital · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
14 Years to 80 Years
Sex
All
01

Study summary

100 patients ASA I-III, undergoing total knee arthroplasty under spinal anesthesia, will be randomly assigned into one of two groups, namely group A (n=50), where an adductor canal block and an IPACK block will be performed preoperatively and group B (n=50) where an adductor canal block only will be performed preoperatively. All patients will receive a standardized multimodal approach, including pregabalin, paracetamol, and PCA with morphine. NRS scores in static and dynamic conditions during the first 48 hours postoperatively, morphine consumption during the first 24 hours postoperatively will be measured and additionally, patient satisfaction, complications, range of knee motion, moblization, functionality, delirium ocurence will be recorded. Chronic pain will be assessed in 3 and 6 months postoperatively.

02

Conditions studied

  • Total Knee Arthroplasty

Keywords

  • arthroplasty
  • replacement
  • knee
03

In context

Lead sponsor

Asklepieion Voulas General Hospital is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physical status according to (ASA) I-III
  • Patients scheduled for total knee arthroplasty

Exclusion criteria

Exclusion Criteria:

  • Previous operation on same knee
  • of spinal anesthesia, peripheral nerve blocks or any of the agents used in the protocol
  • above 32
  • Serious psychiatric, mental and cognitive disorders
  • Language barrier
  • Block failure
  • Chronic opioid, gabapentinoid use
  • Severe kidney disfunction
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Group A

    Drug: Adductor Canal Block plus IPACK Block

  • Active comparator
    Group B

    Drug: Adductor Canal Block

Interventions

  • DrugAdductor Canal Block plus IPACK Block

    Adductor Canal Block plus IPACK Block using Ropivacaine

  • DrugAdductor Canal Block

    Adductor Canal Block using Ropivacaine

06

What researchers measure

Primary outcomes

  1. NRS scores

    Numerical Rating Scale (NRS) scores (Range 0-10, 0=no pain, 10=the worse pain ever)

    Time frame: 48 hours

  2. Morphine consumption

    Morphine consumption in mg

    Time frame: 24 hours

  3. Chronic pain

    Using of Graded Chronic Pain Scale (GCPS) Grade 0: No pain in prior 6 months Grade 1: Low Intensity - Low Disability Grade II: High Intensity Characteristic Pain Intensity - Low Disability Grade III: High Disability - Moderately Limiting Grade IV: High Disability - Severely Limiting

    Time frame: 6 months

Secondary outcomes

  1. Delirium occurence

    Nu-DESK scale (presence of disorientation, inappropriate behavior, inappropriate communication,illusions/hallucinations, psychomoter retardation). Each of the 5 items is rated from 0 to 2. A total of 10 is the maximum score. A score of more than 2 identifies the presence of delirium.

    Time frame: 48 hours

  2. Range of knee motion

    Degrees of flexion

    Time frame: 48 hours

  3. Complications

    Time frame: 48 hours

  4. Patient mobilization

    Patient reporting time of first standing to the side of the bed and number of steps per day

    Time frame: 5 days

  5. Patient satisfaction

    Patients asked whether they would choose the same anaesthetic management in a future operation: Yes/No

    Time frame: 48 hours

  6. Joint function

    Maximal flexion / extension

    Time frame: 6 months

  7. Intestinal function

    Time of first passing of rectal gas, reported by the patient

    Time frame: 5 days

07

Study locations

1 of 1 sites recruiting
  • Asklepieion Hospital of Voula
    Athens, 16673, Greece
    Recruiting
    • Alexandros Makris, Dr · Contact
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03692858
Lead sponsor
Asklepieion Voulas General Hospital
Collaborators
Aikaterini Kalampokini, Chryssoula Staikou
Responsible party
Alexandros Makris (Consultant Anesthesiologist, Asklepieion Voulas General Hospital) — Principal investigator
First posted
Oct 2, 2018
Start date
Oct 1, 2018
Primary completion
Jun 2020 (estimated)
Completion
Jul 2020 (estimated)
Last update
Oct 22, 2019

Study contacts

Alexandros Makris
Contact
makrisalexandros@hotmail.com
+306947076446

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion